IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma

Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 an...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Wang, Zewei [verfasserIn] Xu, Le Chang, Yuan Zhou, Lin Fu, Hangcheng Zhang, Weijuan Yang, Yuanfeng Xu, Jiejie

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2016

Schlagwörter:	Clear-cell renal cell carcinoma Interleukin-33 Prognostic biomarker Overall survival

Anmerkung:	© International Society of Oncology and BioMarkers (ISOBM) 2016

Übergeordnetes Werk:	Enthalten in: Tumor biology - Amsterdam : IOS Press, 1987, 37(2016), 8 vom: 01. März, Seite 11127-11134
Übergeordnetes Werk:	volume:37 ; year:2016 ; number:8 ; day:01 ; month:03 ; pages:11127-11134

Links:	Volltext

DOI / URN:	10.1007/s13277-016-4879-3

Katalog-ID:	SPR031177719

Internformat


LEADER	01000caa a22002652 4500
001	SPR031177719
003	DE-627
005	20230519074623.0
007	cr uuu---uuuuu
008	201007s2016 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s13277-016-4879-3 \|2 doi
035			\|a (DE-627)SPR031177719
035			\|a (SPR)s13277-016-4879-3-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Wang, Zewei \|e verfasserin \|4 aut
245	1	0	\|a IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma
264		1	\|c 2016
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © International Society of Oncology and BioMarkers (ISOBM) 2016
520			\|a Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery.
650		4	\|a Clear-cell renal cell carcinoma \|7 (dpeaa)DE-He213
650		4	\|a Interleukin-33 \|7 (dpeaa)DE-He213
650		4	\|a Prognostic biomarker \|7 (dpeaa)DE-He213
650		4	\|a Overall survival \|7 (dpeaa)DE-He213
700	1		\|a Xu, Le \|4 aut
700	1		\|a Chang, Yuan \|4 aut
700	1		\|a Zhou, Lin \|4 aut
700	1		\|a Fu, Hangcheng \|4 aut
700	1		\|a Zhang, Weijuan \|4 aut
700	1		\|a Yang, Yuanfeng \|4 aut
700	1		\|a Xu, Jiejie \|4 aut
773	0	8	\|i Enthalten in \|t Tumor biology \|d Amsterdam : IOS Press, 1987 \|g 37(2016), 8 vom: 01. März, Seite 11127-11134 \|w (DE-627)300897855 \|w (DE-600)1483579-4 \|x 1423-0380 \|7 nnns
773	1	8	\|g volume:37 \|g year:2016 \|g number:8 \|g day:01 \|g month:03 \|g pages:11127-11134
856	4	0	\|u https://dx.doi.org/10.1007/s13277-016-4879-3 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_22
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_63
912			\|a GBV_ILN_95
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_370
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4338
951			\|a AR
952			\|d 37 \|j 2016 \|e 8 \|b 01 \|c 03 \|h 11127-11134

Indexfelder

author_variant	z w zw l x lx y c yc l z lz h f hf w z wz y y yy j x jx
matchkey_str	article:14230380:2016----::l3ssoitdihnaoalpsoeaieuvvlfainsihl
hierarchy_sort_str	2016
publishDate	2016
allfields	10.1007/s13277-016-4879-3 doi (DE-627)SPR031177719 (SPR)s13277-016-4879-3-e DE-627 ger DE-627 rakwb eng Wang, Zewei verfasserin aut IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © International Society of Oncology and BioMarkers (ISOBM) 2016 Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery. Clear-cell renal cell carcinoma (dpeaa)DE-He213 Interleukin-33 (dpeaa)DE-He213 Prognostic biomarker (dpeaa)DE-He213 Overall survival (dpeaa)DE-He213 Xu, Le aut Chang, Yuan aut Zhou, Lin aut Fu, Hangcheng aut Zhang, Weijuan aut Yang, Yuanfeng aut Xu, Jiejie aut Enthalten in Tumor biology Amsterdam : IOS Press, 1987 37(2016), 8 vom: 01. März, Seite 11127-11134 (DE-627)300897855 (DE-600)1483579-4 1423-0380 nnns volume:37 year:2016 number:8 day:01 month:03 pages:11127-11134 https://dx.doi.org/10.1007/s13277-016-4879-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338 AR 37 2016 8 01 03 11127-11134
spelling	10.1007/s13277-016-4879-3 doi (DE-627)SPR031177719 (SPR)s13277-016-4879-3-e DE-627 ger DE-627 rakwb eng Wang, Zewei verfasserin aut IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © International Society of Oncology and BioMarkers (ISOBM) 2016 Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery. Clear-cell renal cell carcinoma (dpeaa)DE-He213 Interleukin-33 (dpeaa)DE-He213 Prognostic biomarker (dpeaa)DE-He213 Overall survival (dpeaa)DE-He213 Xu, Le aut Chang, Yuan aut Zhou, Lin aut Fu, Hangcheng aut Zhang, Weijuan aut Yang, Yuanfeng aut Xu, Jiejie aut Enthalten in Tumor biology Amsterdam : IOS Press, 1987 37(2016), 8 vom: 01. März, Seite 11127-11134 (DE-627)300897855 (DE-600)1483579-4 1423-0380 nnns volume:37 year:2016 number:8 day:01 month:03 pages:11127-11134 https://dx.doi.org/10.1007/s13277-016-4879-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338 AR 37 2016 8 01 03 11127-11134
allfields_unstemmed	10.1007/s13277-016-4879-3 doi (DE-627)SPR031177719 (SPR)s13277-016-4879-3-e DE-627 ger DE-627 rakwb eng Wang, Zewei verfasserin aut IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © International Society of Oncology and BioMarkers (ISOBM) 2016 Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery. Clear-cell renal cell carcinoma (dpeaa)DE-He213 Interleukin-33 (dpeaa)DE-He213 Prognostic biomarker (dpeaa)DE-He213 Overall survival (dpeaa)DE-He213 Xu, Le aut Chang, Yuan aut Zhou, Lin aut Fu, Hangcheng aut Zhang, Weijuan aut Yang, Yuanfeng aut Xu, Jiejie aut Enthalten in Tumor biology Amsterdam : IOS Press, 1987 37(2016), 8 vom: 01. März, Seite 11127-11134 (DE-627)300897855 (DE-600)1483579-4 1423-0380 nnns volume:37 year:2016 number:8 day:01 month:03 pages:11127-11134 https://dx.doi.org/10.1007/s13277-016-4879-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338 AR 37 2016 8 01 03 11127-11134
allfieldsGer	10.1007/s13277-016-4879-3 doi (DE-627)SPR031177719 (SPR)s13277-016-4879-3-e DE-627 ger DE-627 rakwb eng Wang, Zewei verfasserin aut IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © International Society of Oncology and BioMarkers (ISOBM) 2016 Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery. Clear-cell renal cell carcinoma (dpeaa)DE-He213 Interleukin-33 (dpeaa)DE-He213 Prognostic biomarker (dpeaa)DE-He213 Overall survival (dpeaa)DE-He213 Xu, Le aut Chang, Yuan aut Zhou, Lin aut Fu, Hangcheng aut Zhang, Weijuan aut Yang, Yuanfeng aut Xu, Jiejie aut Enthalten in Tumor biology Amsterdam : IOS Press, 1987 37(2016), 8 vom: 01. März, Seite 11127-11134 (DE-627)300897855 (DE-600)1483579-4 1423-0380 nnns volume:37 year:2016 number:8 day:01 month:03 pages:11127-11134 https://dx.doi.org/10.1007/s13277-016-4879-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338 AR 37 2016 8 01 03 11127-11134
allfieldsSound	10.1007/s13277-016-4879-3 doi (DE-627)SPR031177719 (SPR)s13277-016-4879-3-e DE-627 ger DE-627 rakwb eng Wang, Zewei verfasserin aut IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © International Society of Oncology and BioMarkers (ISOBM) 2016 Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery. Clear-cell renal cell carcinoma (dpeaa)DE-He213 Interleukin-33 (dpeaa)DE-He213 Prognostic biomarker (dpeaa)DE-He213 Overall survival (dpeaa)DE-He213 Xu, Le aut Chang, Yuan aut Zhou, Lin aut Fu, Hangcheng aut Zhang, Weijuan aut Yang, Yuanfeng aut Xu, Jiejie aut Enthalten in Tumor biology Amsterdam : IOS Press, 1987 37(2016), 8 vom: 01. März, Seite 11127-11134 (DE-627)300897855 (DE-600)1483579-4 1423-0380 nnns volume:37 year:2016 number:8 day:01 month:03 pages:11127-11134 https://dx.doi.org/10.1007/s13277-016-4879-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338 AR 37 2016 8 01 03 11127-11134
language	English
source	Enthalten in Tumor biology 37(2016), 8 vom: 01. März, Seite 11127-11134 volume:37 year:2016 number:8 day:01 month:03 pages:11127-11134
sourceStr	Enthalten in Tumor biology 37(2016), 8 vom: 01. März, Seite 11127-11134 volume:37 year:2016 number:8 day:01 month:03 pages:11127-11134
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Clear-cell renal cell carcinoma Interleukin-33 Prognostic biomarker Overall survival
isfreeaccess_bool	false
container_title	Tumor biology
authorswithroles_txt_mv	Wang, Zewei @@aut@@ Xu, Le @@aut@@ Chang, Yuan @@aut@@ Zhou, Lin @@aut@@ Fu, Hangcheng @@aut@@ Zhang, Weijuan @@aut@@ Yang, Yuanfeng @@aut@@ Xu, Jiejie @@aut@@
publishDateDaySort_date	2016-03-01T00:00:00Z
hierarchy_top_id	300897855
id	SPR031177719
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031177719</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519074623.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13277-016-4879-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031177719</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13277-016-4879-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wang, Zewei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© International Society of Oncology and BioMarkers (ISOBM) 2016</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clear-cell renal cell carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Interleukin-33</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognostic biomarker</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Overall survival</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Le</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chang, Yuan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Lin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fu, Hangcheng</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Weijuan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Yuanfeng</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Jiejie</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Tumor biology</subfield><subfield code="d">Amsterdam : IOS Press, 1987</subfield><subfield code="g">37(2016), 8 vom: 01. März, Seite 11127-11134</subfield><subfield code="w">(DE-627)300897855</subfield><subfield code="w">(DE-600)1483579-4</subfield><subfield code="x">1423-0380</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:37</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:8</subfield><subfield code="g">day:01</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:11127-11134</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13277-016-4879-3</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">37</subfield><subfield code="j">2016</subfield><subfield code="e">8</subfield><subfield code="b">01</subfield><subfield code="c">03</subfield><subfield code="h">11127-11134</subfield></datafield></record></collection>
author	Wang, Zewei
spellingShingle	Wang, Zewei misc Clear-cell renal cell carcinoma misc Interleukin-33 misc Prognostic biomarker misc Overall survival IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma
authorStr	Wang, Zewei
ppnlink_with_tag_str_mv	@@773@@(DE-627)300897855
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1423-0380
topic_title	IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma Clear-cell renal cell carcinoma (dpeaa)DE-He213 Interleukin-33 (dpeaa)DE-He213 Prognostic biomarker (dpeaa)DE-He213 Overall survival (dpeaa)DE-He213
topic	misc Clear-cell renal cell carcinoma misc Interleukin-33 misc Prognostic biomarker misc Overall survival
topic_unstemmed	misc Clear-cell renal cell carcinoma misc Interleukin-33 misc Prognostic biomarker misc Overall survival
topic_browse	misc Clear-cell renal cell carcinoma misc Interleukin-33 misc Prognostic biomarker misc Overall survival
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Tumor biology
hierarchy_parent_id	300897855
hierarchy_top_title	Tumor biology
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)300897855 (DE-600)1483579-4
title	IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma
ctrlnum	(DE-627)SPR031177719 (SPR)s13277-016-4879-3-e
title_full	IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma
author_sort	Wang, Zewei
journal	Tumor biology
journalStr	Tumor biology
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2016
contenttype_str_mv	txt
container_start_page	11127
author_browse	Wang, Zewei Xu, Le Chang, Yuan Zhou, Lin Fu, Hangcheng Zhang, Weijuan Yang, Yuanfeng Xu, Jiejie
container_volume	37
format_se	Elektronische Aufsätze
author-letter	Wang, Zewei
doi_str_mv	10.1007/s13277-016-4879-3
title_sort	il-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma
title_auth	IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma
abstract	Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery. © International Society of Oncology and BioMarkers (ISOBM) 2016
abstractGer	Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery. © International Society of Oncology and BioMarkers (ISOBM) 2016
abstract_unstemmed	Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery. © International Society of Oncology and BioMarkers (ISOBM) 2016
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_22 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_63 GBV_ILN_95 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_370 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4338
container_issue	8
title_short	IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma
url	https://dx.doi.org/10.1007/s13277-016-4879-3
remote_bool	true
author2	Xu, Le Chang, Yuan Zhou, Lin Fu, Hangcheng Zhang, Weijuan Yang, Yuanfeng Xu, Jiejie
author2Str	Xu, Le Chang, Yuan Zhou, Lin Fu, Hangcheng Zhang, Weijuan Yang, Yuanfeng Xu, Jiejie
ppnlink	300897855
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s13277-016-4879-3
up_date	2024-07-03T22:26:16.142Z
_version_	1803598510049722368
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031177719</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519074623.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13277-016-4879-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031177719</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13277-016-4879-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wang, Zewei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© International Society of Oncology and BioMarkers (ISOBM) 2016</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clear-cell renal cell carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Interleukin-33</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognostic biomarker</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Overall survival</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Le</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chang, Yuan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Lin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fu, Hangcheng</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Weijuan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Yuanfeng</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Jiejie</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Tumor biology</subfield><subfield code="d">Amsterdam : IOS Press, 1987</subfield><subfield code="g">37(2016), 8 vom: 01. März, Seite 11127-11134</subfield><subfield code="w">(DE-627)300897855</subfield><subfield code="w">(DE-600)1483579-4</subfield><subfield code="x">1423-0380</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:37</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:8</subfield><subfield code="g">day:01</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:11127-11134</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13277-016-4879-3</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">37</subfield><subfield code="j">2016</subfield><subfield code="e">8</subfield><subfield code="b">01</subfield><subfield code="c">03</subfield><subfield code="h">11127-11134</subfield></datafield></record></collection>
score	7.4012585

Nicht das Richtige dabei?

Schreiben Sie uns!

IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?